the phase 3 embraca study of talazoparib in brca-related metastatic breast cancer
Published 9 years ago • 846 plays • Length 3:52Download video MP4
Download video MP3
Similar videos
-
2:07
parp inhibitors and the embraca study of talazoparib in brca-related metastatic breast cancer
-
3:45
current research into treatments for brca-related breast cancer and the phase 3 embraca trial
-
3:27
tripathy discusses a study of talazoparib in brca-mutated advanced breast cancer
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
9:21
dr. litton on activity of talazoparib in advanced brca1/2 breast cancer
-
0:58
dr. litton on the embraca trial in advanced brca1/2 breast cancer
-
2:47
embraca: results of talazoparib vs chemotherapy relative to prior ct in patients with advanced b...
-
2:02
dr. litton on a study of neoadjuvant talazoparib for patients with brca-mutated tnbc
-
1:58
dr. joanne blum on the embraca trial in metastatic brca-mutant breast cancer
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?
-
3:31
distinguishing between parp inhibitors in breast cancer
-
3:52
talazoparib in locally advanced or metastatic breast cancer
-
4:03
novel parp inhibitor boosts pfs in her2– breast cancer with brca mutations
-
1:12
dr. joanne blum on the function of talazoparib in locally advanced and/or metastatic breast cancer
-
1:12
neelima denduluri, md, regarding the embraca trial in her2- metastatic breast cancer
-
5:03
the mechanisms of brca-related breast cancer and molecular profiling
-
1:16
parp inhibitors improve outcomes, qol in breast cancer
-
6:04
germline brca mutations in tnbc
-
3:58
brca breast cancer: the advent of parp inhibitors